FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
nours per response	e 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person * MANZO MICHAEL P.				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below)						
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 05/05/2020							V	P of Enginee	ering			
(Street) WALTHAM, MA 02452			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person							
(City)	(State)	(Zip)	T	able I - N	Non-E	Derivativ	ve Se	ecurities	Acqui	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transa Code (Instr. 8)			(A) or Disposed of				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership o Form: B Direct (D) C	Beneficial Ownership		
					Cod	e	V Am	ount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)	
Common	Common Stock 05/05/2020			F <u>(1</u>)	93			\$ 5.1	18,076			D			
Reminder:	Report on a s	separate line fo		Derivative Securit	ies Acqu	Pe co th	ersons ontained e form Dispose	who d in t disp	respon this for plays a c	m are curre	not requesting ntly valid	OMB con	formation spond unle trol numbe	ess	1474 (9-02)	
1 7711 0	I _a	2 77	,	e.g., puts, calls, w						1 -	1	0 D : 0	0.37 1	6 10	11.37.	
Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/	Execution Date (Year)	3A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transaction Code (Instr. 8) (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Amo Und Secu	ount of lerlying Security Setr. 3 and Control of lerlying Security Setr. 3 and Security Secur		9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	tive Ownership form of Derivative Security: Direct (D) or Indirect ction(s)	nership m of rivative curity: ect (D) ndirect					
				Code V	(A) (I	Е	Oate Exercisab		xpiration Date	Title	Amount or Number of Shares					

Reporting Owners

Reporting Owner Name / Address		Relationships					
		10% Owner	Officer	Other			
MANZO MICHAEL P. C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Engineering				

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	05/06/2020
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 05/01/2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.